Profound Medical Corp (PROF) News & EventsPROFProfound Medical Corp

Profound Medical Enters Supply Agreement with Cook Medical

Profound Medical announced that it has entered into a supply and distribution agreement with the iMRI Division of Cook Medical to expand U.S. sales of its Tulsa-Pro system. The iMRI Suite, developed by Cook Medical and Siemens Healthineers, is a fully integrated procedural environment that enables real-time MRI-guided interventions without ionizing radiation. It is built for intervention from the ground up. Cook's Copernicus program connects the iMRI Suite with designed-for-MRI devices, clinical training, implementation support, and partner therapies, giving hospitals a single pathway from planning an iMRI program to treating patients. Under the agreement, Cook will purchase Tulsa-Pro systems from Profound at a predetermined transfer price for distribution in the United States. Customers purchasing systems through Cook will obtain single-use disposables and service contracts directly from Profound.

Profound Medical Enters Co-Education Agreement with Telix Pharmaceuticals

Profound Medical (PROF) announced it is entering into a co-education agreement with Telix Pharmaceuticals (TLX). The agreement establishes a framework through which the companies intend to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's advanced prostate-specific membrane antigen targeting PET molecular imaging technologies, Gozellix and Illuccix, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO platform across the prostate care continuum. Planned initiatives include participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs and webinars, as well as the development of educational content, clinical case studies and best-practice materials. The collaboration is intended to increase physician awareness of PSMA-informed treatment pathways, support appropriate patient selection and treatment planning, and expand access to the TULSA Procedure.

Profound Expects Q3 Gross Margin Over 70%

Sees Q3 gross margin over 70%. "The significant increase in revenue we expect to report this quarter represents a historic milestone for Profound, reflecting the strong commercial momentum building behind our technology," said Arun Menawat, Profound's CEO and chairman. "The expected year-over-year and sequential growth in the third quarter reflects increased commercial activity across our installed base and new customer accounts."